Clik here to view.
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b...
BURLINGAME, Calif. Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with...
View ArticleClik here to view.
PTT Invests in Lotus Pharmaceutical’s Strategic Partnership in South East Asia
TAIPEI, Taiwan Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be...
View ArticleClik here to view.
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental...
BOTHELL, Wash. & TOKYO Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug Administration...
View ArticleClik here to view.
Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
SYDNEY Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its...
View ArticleClik here to view.
Ultivue Announces $50M Financing Round
CAMBRIDGE, Mass. Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue...
View ArticleClik here to view.
An Open Letter to Users of Cyclotrons (up to 20 MeV), PETNET, Nuclear...
WASHINGTON & OTTAWA, Ontario & NEW DELHI, India Best ABT, a company of TeamBest Global (TBG) Group, is planning to introduce a new cyclotron — the Best Sub-Compact Model 200 — which can...
View ArticleClik here to view.
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review...
View ArticleClik here to view.
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by...
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) against...
View ArticleClik here to view.
Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021...
View ArticleClik here to view.
アルティビューが5000万ドルの資金調達ラウンドを発表
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 組織表現型解析においてマルチプレックスバイオマーカー分析を同じスライドによる従来のH&E法と組み合わせた独自手法で精密医療ソリューションを前進させているリーダー企業のアルティビューは本日、5000万ドルのシリーズD資金調達ラウンドを完了したと発表しました。新たな投資企業として、Ally Bridge...
View ArticleClik here to view.
临床数据显示，Noxopharm的Veyonda®或可预防细胞因子风暴
悉尼 (美国商业资讯)–澳大利亚临床阶段药物开发公司Noxopharm Limted (ASX:NOX)今天宣布，其针对一组18例新冠肺炎中重度病例的NOXCOVID研究的中期数据显示，Veyonda可延缓与该病恶化相关的重度炎症进程。 Noxopharm首席执行官Graham...
View ArticleClik here to view.
ノクソファームのビヨンダがサイトカインストームを予防し得ることを示す臨床データ
シドニー （ビジネスワイヤ） — オーストラリアの臨床段階医薬品開発企業であるノクソファーム・リミテッド（ASX:NOX）は本日、中等度のCOVID-19症状を抱える患者18人のコホートにおいて、NOXCOVID試験の中間データから、ビヨンダが症状の悪化に伴う重度の炎症の進行を予防することが示されたと発表しました。...
View ArticleClik here to view.
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive...
FOSTER CITY, Calif. & BEIJING Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and CANbridge Pharmaceuticals, Inc., announced today that they have entered into a licensing agreement, pursuant to which...
View ArticleClik here to view.
Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing
SYDNEY Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) today announced its CEP-2 study will begin shortly. CEP-2 is related to the Investigational New Drug (IND)...
View ArticleClik here to view.
Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against...
CHENGDU, China Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today progress in its MYC-synthetic lethal (MYC-SL) programme. The Company has...
View ArticleClik here to view.
Nanobiotix与联拓生物宣布达成战略合作，将携手在中国和亚洲其他市场对潜在首创的放射增强剂NBTXR3进行开发和商业化，涵盖多个瘤种和不同联合治疗方案
巴黎、剑桥（美国马萨诸塞州）、上海、普林斯顿（美国新泽西州）...
View ArticleClik here to view.
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential...
PARIS & CAMBRIDGE, Mass. & SHANGHAI & PRINCETON, N.J. Regulatory News: This press release features multimedia. View the full release here:...
View ArticleClik here to view.
マグバイオ・ジェノミクスがMawi iSWAB-RNA v2向けにThermofisher KingFisher™...
米カリフォルニア州ヘイワード （ビジネスワイヤ） — 生体試料調製のための革新的な技術の開発に傾注しているバイオテクノロジー企業のマウィDNAテクノロジーズは、マグバイオ・ジェノミクスが同社のHighPrep™ Total RNA Isolation Kit – iSWAB™（HighPrep™トータルRNA分離キット – iSWAB™）を用いて、Thermofisher...
View ArticleClik here to view.
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and rare cancers in China and...
View ArticleClik here to view.
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced...
View Article